Is CJC-1295 Legal in Australia?

The short answer

CJC-1295 is not approved by the Therapeutic Goods Administration (TGA) for human use in Australia, and no CJC-1295 product appears on the Australian Register of Therapeutic Goods (ARTG). As a synthetic growth-hormone-releasing hormone (GHRH) analogue, it is captured by the Poisons Standard as a prescription-only substance, which means it cannot lawfully be supplied to the general public for personal use. In practice, CJC-1295 is handled in Australia as a laboratory research compound only, supplied for in-vitro and laboratory investigation, and is not for human or animal consumption.

That framing matters. The lawful, conservative way to describe CJC-1295 is as an unapproved, investigational peptide that is sold to researchers for scientific work, never as a product for personal health. The rest of this guide explains where it sits in Australian regulation, how it should be labelled, and what compliant sourcing looks like.

What CJC-1295 actually is

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). In the research literature it is grouped with the growth hormone secretagogues, a class of compounds studied in laboratory settings for their interaction with the GHRH receptor. It is a modified peptide sequence based on the first 29 amino acids of native GHRH, with substitutions intended to slow enzymatic breakdown in experimental conditions.

It is important to separate what a compound is from any claim about what it does for a person. This article describes CJC-1295 only as a chemical of research interest. It makes no therapeutic, performance, recovery or body-composition claims, and none should be inferred.

TGA status: unapproved and not on the ARTG

The central regulatory fact is that CJC-1295 has not been evaluated or approved by the TGA as a therapeutic good for human use. No CJC-1295 medicine is listed on the ARTG, which is the public register of goods approved for supply in Australia. A substance that is not on the ARTG has not passed the TGA's assessment for quality, safety and efficacy as a medicine.

Because it is an unapproved substance that falls within a prescription-only class, CJC-1295 cannot be marketed, advertised or supplied to consumers as a medicine or supplement. The TGA has publicly identified peptides of this kind as examples of unapproved products that are sometimes sold illegitimately. For a research supplier, the only defensible position is to describe and label CJC-1295 strictly as a research chemical that is not for human or animal use.

• Not approved by the TGA for human use
• Not listed on the Australian Register of Therapeutic Goods (ARTG)
• Classified within a prescription-only (Schedule 4) framework as a GHRH analogue
• Cannot be advertised or supplied to the public as a medicine or supplement

Where it sits alongside growth hormone and other secretagogues

Human growth hormone (somatropin) is a Schedule 4 prescription-only medicine in Australia and is tightly controlled. CJC-1295 does not contain growth hormone, but as a GHRH analogue and growth hormone secretagogue it is regulated conservatively and is treated as a prescription-only type substance rather than something freely available to the public.

This is the same cautious posture Australian regulators apply across the broader peptide category. Compounds that are investigational, or that influence hormonal pathways, are kept out of general retail supply. You can see the same pattern in our regulation guides for other peptides, such as BPC-157 and tirzepatide, where the common thread is unapproved status and restricted supply.

Is BPC-157 legal in Australia? Is tirzepatide legal in Australia?

WADA and sport: prohibited at all times

For anyone involved in competitive or tested sport, the position is clear. The World Anti-Doping Agency (WADA) prohibits growth hormone secretagogues and GHRH analogues, including CJC-1295, under the S2 category of its Prohibited List. These substances are banned at all times, meaning both in-competition and out-of-competition.

This is a factual statement about anti-doping rules, not advice to use anything. Athletes and support staff bound by the WADA Code should treat CJC-1295 as a prohibited substance and refer to their anti-doping authority for the current list.

CJC-1295 with DAC versus without DAC (mod GRF 1-29)

Researchers often encounter two related forms, and the distinction is purely a matter of chemistry. CJC-1295 without DAC is commonly called modified GRF (1-29), or mod-GRF 1-29. It is based on the 29-amino-acid GHRH fragment with substitutions and a C-terminal amide, and in laboratory characterisation it has a comparatively short duration before breakdown.

CJC-1295 with DAC carries an additional element, a drug affinity complex (DAC), built from a lysine residue bearing a maleimidopropionyl group. In research descriptions this modification is reported to bind serum albumin, which extends how long the molecule persists compared with the without-DAC form. The two are distinct molecules with different molecular weights and different reported half-lives.

Both are described here only at the structural and chemical level. We do not provide dosing, reconstitution amounts, administration routes or any usage protocol. For a factual research profile of the shorter form, see our dedicated pages below.

• Without DAC (mod-GRF 1-29): the 29-residue GHRH-based sequence, shorter reported duration in research settings
• With DAC: the same core plus a drug affinity complex that binds albumin, longer reported persistence
• Different molecules, different molecular weights, different reported half-lives

CJC-1295 no DAC research profile CJC-1295 no DAC + Ipamorelin blend

Compliant labelling and documentation

Because CJC-1295 is unapproved, the labelling expectations for a legitimate research supply are strict. Product information should state clearly that the item is a research chemical, intended for laboratory research use only, and not for human or animal consumption. It should avoid any medical, therapeutic, performance or body-composition language that would imply personal use.

Serious research suppliers also back their material with documentation. A certificate of analysis (CoA) from independent testing records identity and purity for a given batch. Knowing how to read that documentation is part of sourcing responsibly, and it helps separate credible suppliers from the many illegitimate operators the TGA has warned about.

• Labelled as research-use-only, not for human or animal consumption
• No therapeutic, performance or efficacy claims on the listing
• A batch-specific certificate of analysis available for identity and purity
• Clear supplier identity and contactable Australian business details

What compliant sourcing looks like in Australia

For a research buyer, compliant sourcing means buying from a transparent Australian supplier that frames its catalogue as research chemicals, publishes batch testing, and never markets the material for personal use. It also means understanding that importing or possessing an unapproved prescription-type substance for personal use can breach the Poisons Standard and Commonwealth import law, and that parcels of unapproved peptides are routinely stopped at the border.

If you are evaluating a supplier, the practical checks are documentation, honesty about regulatory status, and local accountability. Our guides on reading a certificate of analysis and spotting a trustworthy supplier walk through exactly what to look for.

How to read a peptide certificate of analysis How to spot a trustworthy supplier